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 The treatment of ischemic stroke remains one of the most challenging areas in 
medicine. To date, the only treatment approved by health authorities is early reperfusion by 
the thrombolytic agent, recombinant tissue-type plasminogen activator (rt-PA)1. Nevertheless, 
despite benefit from fibrinolysis, several limitations are linked to the use of rt-PA, including a 
clinically relevant risk of haemorrhage1 and a highly suspected risk of neurotoxicity2,3.  
Desmoteplase (DSPA) is a highly fibrin-specific recombinant plasminogen activator (PA) 
isolated from the saliva of the vampire bat Desmodus rotundus4. Experimental data suggest 
that DSPA could display several advantages: i) in contrast to rt-PA, DSPA is devoid of pro-
excitotoxic effects both in vitro and in vivo5,6; ii) intravenous DSPA significantly reduces the 
passage of co-administered rt-PA across the intact BBB and the attendant aggravation of 
excitotoxic damage6. In this context, the aim of the present study was to investigate, using a 
predictive in vitro model of BBB7 (Fig. 1A), and an in vivo model of excitotoxicity, whether 
an inactive form of DSPA, clogged DSPA  (cDSPA), could prevent the ability of rt-PA to 
cross the BBB and promote excitotoxic injuries. As previously demonstrated for native 
DSPA6, we found that cDSPA did not alter the integrity of the BBB (passage of sucrose) 
alone or in combination with rt-PA (data not shown) and can cross the BBB, despite being 
catalytically inactive (Fig. 1B). Then, the passage of rt-PA alone or in combination with either 
DSPA or cDSPA was analyzed using both fluorogenic proteolytic (spectrozyme®) and 
zymography assays (Fig. 1C and D). Both DSPA and cDSPA reduced the passage of rt-PA by 
around 30% in our in vitro BBB model. The effects of intravenous injection of rt-PA and 
cDSPA were studied in a mouse model of excitoxicity induced by a striatal stereotaxic 
injection of NMDA (Figure 1E). Neither rt-PA nor cDSPA vehicles injected intravenously 
altered the extent of NMDA-induced striatal injury. As previously demonstrated6, the 
systemic injection of rt-PA increased the striatal lesion volume seen with NMDA by almost 
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60% (from ~10 to ~16 mm3). Interestingly, intravenous co-administration of cDSPA with rt-
PA, both at 1 mg/kg, suppressed the ability of exogenous rt-PA to enhance NMDA-induced 
lesion. No micro-haemorrhages were detected in animals treated with rt-PA and/or clogged-
desmoteplase. 
 Endogenous tPA, released by vascular endothelial cells, is well-known to play a 
critical role as a thrombolytic enzyme that activates plasminogen to plasmin. Based on this 
activity, exogenous rt-PA-induced thrombolysis remains the only FDA-approved drug for the 
treatment of patients in acute ischemic stroke1. However, t-PA favors intracerebral 
hemorrhagic transformation, limiting the licensed use of this drug to a 3 hours post-ictus 
therapeutic window1. Accordingly, the balance between the beneficial effects of thrombolysis 
and the injurious cerebral effects of rt-PA may be improved by restricting the access of 
vascular rt-PA to the brain parenchyma. Previously, we and others have demonstrated both in 
vitro and in vivo that despite its common ability to cross the intact BBB trough a common 
transport system, in contrast to rt-PA, DSPA, is not pro-neurotoxic6. As a further 
characterization of the transport mechanism, our results show that a proteolytically inactive 
form of DSPA can restrict rt-PA trans-BBB passage. This is in agreement with the previous 
demonstration that PAs can cross the BBB independently of their proteolytic 
activity/domain8. We also demonstrate that clogged-desmoteplase prevents exogenous rt-PA-
promoted excitotoxicity in vivo. This is in agreement with previous demonstrations that DSPA 
can prevent cerebral damage by rt-PA in vivo5,6 a feature likely to contribute to the increased 
tolerance and safety of the clinical use of DSPA in the 3-9 hours time window post-onset of 
stroke symptoms9. Thus, while rt-PA remains the only approved thrombolytic drug to treat 
stroke patients, the interest in alternatives like DSPA is sustained. As intrinsic fibrinolytic 
activity of such an antagonist would not be required or might even be counterproductive, 
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generation of a proteolytically inactive version of DSPA able to compete with rt-PA for 
transport at the BBB might open the way to a safer use of rt-PA as a thrombolytic in stroke.  
 
Figure 1: (A) Schematic representation of the in vitro BBB model (B) biot-rt-PA or biot-
cDSPAα1 were applied to the upper endothelial compartment. Two hours later, their activities 
or presence in the lower side medium were analyzed either by zymography assay or 
immunoblotting (n=3). (C,D) rt-PA alone or with DSPA or cDSPA was applied to the upper 
endothelial compartment. Two hours later, rt-PA activity was analyzed in the lower side 
medium, either by fluorogenic assay (spectrozyme®) (C) or zymography assay (D). Results 
are normalized to rt-PA (mean values ± SEM of 3 experiments per group; * p<0.05 Mann-
Whitney test). (E) Effects of intravenous injection of tPA alone or in combination with 
cDSPA (1 mg/kg each) on the extent of neuronal death induced by the striatal administration 
of NMDA (10 nmol) in mice (mean ± SD; n=10 per group; *: p<0.01 compared to NMDA 
alone, $: p<0.01 compared to NMDA + tPA, Mann-Whitney test). 
 
Reagents, Human recombinant rt-PA (Actilyse) from Boehringer Ingelheim (Paris, France). 
DSPA was provided by PAION Deutschland GmbH (Aachen, Germany). 
Production of cDSPA: cDSPA was generated by coupling the Phe-Pro-Arg-
chloromethylketone modified tripeptide to DSPA.  
Biotinylation: Since cDSPAα1 has no intrinsic enzymatic activity, we had to develop a 
method of detection for transport studies, based on biotinylation of the compound, allowing 
performing SDS-PAGE/immunoblotting against biotin (with a streptavidin secondary 
antibody). We used the FluoReporter®Biotin-XX Protein Labeling kit (Molecular Probes) 
according to the manufacturer’s instructions.  
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Blood-brain barrier (BBB) in vitro experiments: Transport across the BBB was studied 
using a previously characterized in vitro model7, consisting of a co-culture of endothelial and 
glial cells and shown to closely mimic the in vivo BBB. rt-PA and/or desmoteplase were 
added to the upper side of the endothelial cells. Abluminal and luminal media were harvested 
after the 2 hours transport experiments.  
Spectrozyme
®
 assays were performed using a fluorogenic substrate (Spectrozyme XF444, 
American Diagnostica, Stamford, NJ, USA). 
Zymography assay was performed by adding plasminogen (22.5µg) and casein (5mg) to a 
12.6% SDS polyacrylamide gel.  
Striatal excitotoxic lesions: Mice were anaesthetised with isoflurane and placed in a 
stereotaxic frame. Body temperature was maintained at 37 ± 0.5°C. The skull was exposed 
and an injection pipette was stereotaxically implanted in the right striatum according to the 
atlas of Paxinos & Watson (coordinates 0.5 mm posterior, +/- 2 mm lateral and -3 mm ventral 
to the bregma). NMDA (10 nmol) was injected in a volume of 0.3 µl. Excitotoxic treatment 
was followed after 10 minutes by intravenous injection of rt-PA (1 mg/kg), cDSPA (1 mg/kg), 
rt-PA + cDSPA (1 mg/kg each), tPA vehicle (L-Arg 35 mg/kg, phosphoric acid 10 mg/kg and 
polysorbate 80 0.2%) or cDSPA vehicle (glycine 4 mg/kg and mannitol 10.64 mg/kg).  
Histological analysis: For volume analysis, one coronal section (20 µm) out of every 10 was 
stained with thionine and analysed with an image analyser (Scion Image, Scion Corporation, 
Frederick, Maryland, USA).  
Statistical analysis: For in vitro and in vivo studies, data were expressed as mean ± SEM, and 
statistical analyses were performed using the Kruskal and Wallis test followed by a Mann-
Whitney test for inter-group comparisons. 
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- Based on its fibrinolytic activity, tissue type plasminogen activator (tPA) is the 
only treatment approved so far by the authorities, to treat ischemic stroke 
patients (NINDS, 1995). 
 
- However, exogenous tPA can display deleterious effects on components of the 
neurovascular unit, including promotion of edema and blood-brain barrier (BBB) 
leakage (Aoki et al., Stroke, 2002, Yepes et al., J.Clin. Invest., 2003), which 
probably minimise its overall benefit. 
 
- Moreover, tPA was shown to have the ability to cross both the healthy and 
injured BBB (Benchenane et al., Circulation, 2005), thus adding to the pro-
neurotoxic effect of endogenously produced parenchymal tPA (Tsirka et al., 
Nature, 1995; Nicole et al., Nat. Med., 2001).  
 
- Desmoteplase (DSPA) is a new thrombolytic agent derived from bat salivary 
glands ( Hacke et al., Stroke, 2005), very close to tPA in terms of structural 
determinants, but previously demonstrated to : 
 
- cross the BBB as tPA does (Lopez-Atalaya et al., Stroke, 2007) 
 
- be devoid of pro-neurotoxic effect (Reddrop et al., Stroke, 2005; 
Lopez-Atalaya et al., J Cereb Blood Flow Metab, 2008)  
 
- Although the use of DSPA to treat stroke patients is debated (see DIAS 2 data), we 
provide here the demonstration that : 
 
- a proteolytically inactive form of DSPA can prevent the passage of 
exogenous tPA across the BBB and its subsequent neurotoxic 
activity, thus demonstrating the therapeutic potential of 
competitive inhibitors of tPA’s transport to the brain for stroke 
patients.  
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